Eiger BioPharma (EIGR) PT Raised to $29 at Ladenburg Thalmann Following Lambda's Positive TOGETHER Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. LITE
5. CL
6. TFII
7. LYB
8. NVT
9. SPY
10. AAPL

Go back to Eiger BioPharma (EIGR) PT Raised to $29 at Ladenburg Thalmann Following Lambda's Positive TOGETHER Data

Eiger BioPharmaceuticals (EIGR) Announces Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER

March 17, 2022 8:01 AM EDT

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50% (primary endpoint) and death by 60% in the Phase 3 TOGETHER study, a multi-center, randomized, double-blind, placebo-controlled study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.

The Phase 3 TOGETHER study of Lambda... More